Is HER2-low a distinct subtype of breast cancer?
DESTINY-Breast04: practice-changing results for HER2-low breast cancer
Overview of the management of HER2-low breast cancer patients
The exciting new field of HER2-low breast cancer
HER2-Low Breast Cancer: DESTINY or Good Science?
Questions remaining in the field of HER2-low breast cancer
Remaining questions surrounding HER2-low breast cancer – how low can you go?
Mammography Symposium with László Tabar: Winter Edition 2024 (2/3)
Remaining questions on the management of HER2-low breast cancer
Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in Review
Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate
The evolution of HER2-low-positive breast cancer as a clinical subtype
Clinical outcomes in women with metastatic HER2-low breast cancer in the real world
Latest news in HER2-low breast cancer
Biological behaviour of HER2-low BC is dependent on HR expression
The Science of HER2-low Breast Cancer and Implications for the Pathology Team
Novel treatment options for HER2-low breast cancer
Enisa's story: Elevating hope in HER2-low breast cancer
Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer Paradigm
HER2-Low and HER2-Zero in Breast Cancer: Prognosis & Prediction | Oncotarget